GlobeNewswire by notified

Martin Bernstein Joins Synchronoss Board of Directors

Share

B. Riley Executive Brings Strong Financial Acumen to the Board

BRIDGEWATER, N.J., July 12, 2021 (GLOBE NEWSWIRE) -- Synchronoss Technologies, Inc. (NASDAQ: SNCR), a global leader and innovator of cloud, messaging and digital solutions, is pleased to announce that Martin Bernstein has joined its Board of Directors, effective immediately.

Bernstein was appointed to the Board in connection with the recent recapitalization of Synchronoss, and serves as a representative of B. Riley Financial, Inc. (NASDAQ: RILY) (B. Riley), the company’s largest shareholder.

“On behalf of our entire Board, I am pleased to welcome Marty to our team,” said Stephen Waldis, Founder and Executive Chairman of the Synchronoss Board of Directors. “Marty’s extensive experience in capital allocation strategies, corporate governance and financing will serve our organization well. I have no doubt that his impressive knowledge and extraordinary track record will not only benefit our already strong board, but I fully expect his impact will be key to helping Synchronoss achieve its strategic growth objectives.”

Bernstein represents B. Riley Principal Investments, an affiliate of B. Riley that makes direct investments in companies with proven platform technologies with significant near-term growth potential. He currently serves as Head of Private Investments at B. Riley and is responsible for sourcing, underwriting and managing company investments in addition to leading distribution to the firm's syndication partners. Bernstein has extensive experience leading investments across technology, transportation, automotive, aerospace, manufacturing, power, infrastructure, and other sectors.

Bernstein commented, “It is an honor to join the Synchronoss board after working closely with Steve, Jeff, and the entire Synchronoss team on the recent recapitalization. I share management’s excitement and vision for the company, rooted in continued innovation and a best-in-class suite of white label products for leading telecom customers. We believe the Synchronoss business is at an inflection point and is well-positioned to execute on its growth strategy following the refinancing. I look forward to continuing to work with the team as a member of the board as we endeavor to create value for stakeholders and customers.”

Prior to joining B. Riley in March 2021, Bernstein was with Anchorage Capital responsible for leading investments across capital structures, including public equities, private equity, performing credit, bank debt and distressed debt, and restructuring situations. He previously worked as an analyst at Bocage Capital, and was on the investment team for the endowment at Howard Hughes Medical Institute. Bernstein earned an AB in history from Dartmouth College. He is based in Connecticut.

About Synchronoss

Synchronoss Technologies (NASDAQ: SNCR) builds software that empowers companies around the world to connect with their subscribers in trusted and meaningful ways. The company’s collection of products helps streamline networks, simplify onboarding and engage subscribers to unleash new revenue streams, reduce costs and increase speed to market. Hundreds of millions of subscribers trust Synchronoss products to stay in sync with the people, services and content they love. That’s why more than 1,500 talented Synchronoss employees worldwide strive each day to reimagine a world in sync. Learn more at www.synchronoss.com

Contacts

Media
Anais Merlin, CCgroup (International)
Diane Rose, CCgroup (North America)
synchronoss@ccgrouppr.com

Investors
Todd Kehrli/Joo-Hun Kim, MKR Investor Relations, Inc.
investor@synchronoss.com

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Giambattista Valli dazzles Barcelona during the Bridal Night19.4.2024 12:41:00 CEST | Press release

BARCELONA, Spain, April 19, 2024 (GLOBE NEWSWIRE) -- The most exclusive fashion show of the Barcelona Bridal Fashion Week charmed over 450 guests last night who enjoyed a unique show in the historic building of the Llotja de Mar. The Maison Giambattista Valli exclusively celebrated the runway debut of its bridal collection during the Bridal Night, the gala evening of the event organized by Fira de Barcelona with the support of the Catalan Ministry of Business and Labor. In an extraordinary show, Giambattista Valli's 30 creations shone with their own light. It was a culmination of silhouettes, representing a comprehensive exhibition of Mr. Valli’s concept of contemporary bridal dressing, inviting his audience to witness the manifestation of his vision, translated into a presentation that embodies the essence of individuality, sharing a dream and a celebration and love. The fashion show featured ten dresses from the third “Love Collection,” ten iconic silhouettes from the first and secon

Alvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)19.4.2024 12:10:00 CEST | Press release

Alvotech, in agreement with Teva Pharmaceuticals, has signed an agreement with a strategic partner to bring to the U.S. market the newly FDA approved high-concentration interchangeable biosimilar to Humira®The agreement broadens patient access and further commitment to availability of vital biologics in the U.S. and globally Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today a long-term agreement with a strategic partner to further enhance access to Adalimumab-ryvk in the U.S. market, the newly U.S. Food and Drug Administration (FDA) approved high-concentration interchangeable biosimilar to Humira. “This new partnership agreement supports our financial guidance and reflects Alvotech’s strong commitment to increasing patient access to more affordable healthcare,” said Robert Wessman, Chairman and CEO of Alvotech. The current multi-product commercialization partnership between T

Vaccinologists Keith Klugman and Shabir Madhi Awarded Sabin’s Prestigious Gold Medal; Infectious Diseases Epidemiologist Nicole Basta Receives Rising Star Award19.4.2024 12:00:00 CEST | Press release

WASHINGTON, April 19, 2024 (GLOBE NEWSWIRE) -- The Sabin Vaccine Institute yesterday presented the Albert B. Sabin Gold Medal to physician-researchers Keith Paul Klugman and Shabir Ahmed Madhi, and its Rising Star award to infectious diseases epidemiologist Nicole Elaine Basta at a ceremony in the National Academy of Sciences building in Washington D.C. Klugman and Madhi received the Sabin Gold Medal, one of the highest recognitions for vaccinologists globally, for their seminal combined contributions to the development of vaccines against pneumonia and diarrheal disease – major causes of death in children in low- and middle-income countries (LMICs). Klugman first met his then-graduate student Madhi at South Africa’s University of the Witwatersrand (also known as Wits University), where Klugman established, and Madhi expanded, a now globally renowned infectious diseases research institute. Apart from pneumonia, their work focused on maternal and children’s vaccines including influenza,

Forløb af ordinær generalforsamling 202419.4.2024 11:59:58 CEST | pressemeddelelse

Investeringsforeningen Investin har i dag afholdt ordinær generalforsamling i henhold til tidligere offentliggjort dagsorden. Ledelsens beretning og årsrapporten for 2023, herunder de i januar 2024 udbetalte udlodninger samt bestyrelsens honorar for 2023 blev godkendt af generalforsamlingen. Alle de af bestyrelsen stillede forslag blev vedtaget, herunder overflytning af afdeling I&T Nordiske Aktier Large Cap og afdeling I&T Globale Aktier ESG Select samt vedtægtsændringer. Til bestyrelsen genvalgtes Kim Høibye, Jesper Lau Hansen, Henrik Vincents Johansen samt Tine Roed, og bestyrelsen konstituerede sig efterfølgende med Kim Høibye som formand. Som revisor for foreningen genvalgtes EY Godkendt Revisionspartnerselskab. Eventuelle henvendelser vedrørende denne meddelelse kan rettes til direktør Tage Fabrin-Brasted på tlf. 44 55 91 60. Med venlig hilsen Investeringsforeningen Investin Tage Fabrin-Brasted Direktør

Investeringsforeningen ValueInvest Danmark – Prospektopdatering19.4.2024 11:32:00 CEST | pressemeddelelse

Opdateret prospekt for Investeringsforeningen ValueInvest Danmark offentliggøres dags dato. Der er fore­taget følgende opdateringer i prospektet: Indsættelse af regnskabstal for 2023 Prospektet er vedhæftet denne fondsbørsmeddelelse og kan endvidere downloades på www.valueinvest.dk eller rekvireres ved henvendelse til BI Management A/S, Bredgade 40, 1260 København K, tlf. 77 30 90 00. Med venlig hilsen BI Management A/S Martin Fjordlund Smidt Direktør Vedhæftet fil Prospekt IF ValueInvest Danmark 2024.04.19 FINAL clean inkl. bilag

HiddenA line styled icon from Orion Icon Library.Eye